Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Institut De Cancerologie De L Ouest
Sponsor

Institut De Cancerologie De L Ouest

France Bd Du Professeur Jacques Monod, 44800 Saint-Herblain, France

About the sponsor

Breast cancer research includes triple-negative breast cancer and the management of disease-related complications such as brain metastases. The sponsor also supports work on fertility preservation before systemic treatment, including ovarian stimulation and cryopreservation strategies.

  • Triple-negative breast cancer
  • Brain metastases in breast cancer
  • Fertility preservation before chemotherapy

These activities reflect interest in both disease control and treatment-related quality-of-life issues in women with cancer.

About Specializations

Institut De Cancerologie De L Ouest runs clinical trials in conditions such as Triple negative breast cancer, Breast cancer, Metastases to central nervous system, Neuropathy peripheral, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Triple negative breast cancer

Recruiting

Study of [68Ga]Ga-PentixaFor PET-CT Imaging in Patients with Metastatic Triple-Negative Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:Institut De Cancerologie De L Ouest

Breast cancer

Recruiting

Study of Fertility Preservation Using Tamoxifen, Follitropin Beta, Cetrorelix and Choriogonadotropin Alfa in Women with Breast Cancer Before Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cetrorelix
  • Sponsor:Institut De Cancerologie De L Ouest

Metastases to central nervous system

Recruiting

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut De Cancerologie De L Ouest

Neuropathy peripheral

Recruiting

Study Comparing Capsaicin Patch and Duloxetine for Patients with Chemotherapy-Induced Peripheral Neuropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capsaicin
  • Sponsor:Institut De Cancerologie De L Ouest

Colorectal cancer

Recruiting

Study on Oxaliplatin with Drug Combination for Patients with Advanced Peritoneal Metastasis from Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut De Cancerologie De L Ouest

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Institut De Cancerologie De L Ouest

Metastatic neoplasm+1

Not recruiting

Study on Adding Zoledronic Acid or Denosumab to Radiotherapy for Adults with Inoperable Vertebral Bone Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Institut De Cancerologie De L Ouest

Breast cancer metastatic+2

Not recruiting

Study on Detecting Untreated Brain Metastases in Lung, Breast, and Melanoma Cancer Patients Using Fluorodopa (18F)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorodopa (18F)
  • Sponsor:Institut De Cancerologie De L Ouest

Prostate cancer

Not recruiting

Study on Stereotactic Body Radiation Therapy with or without Durvalumab for Patients with Oligometastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut De Cancerologie De L Ouest

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.